NECC Sales Director Ronzio Pleads Guilty to FDA Fraud

Robert A. Ronzio, 42, of North Providence, R.I., the national sales director for New England Compounding Center (NECC), pleaded guilty in U.S. District Court in Boston to one count of conspiring to defraud the Food and Drug Administration. The guilty plea marks a pivotal development in the sprawling federal case against NECC, the Framingham, Mass.-based compounding pharmacy at the center of the deadliest pharmaceutical disaster in modern U.S. history.

Ronzio admitted that NECC operated not as a licensed pharmacy filling individual prescriptions, but as an underground drug manufacturer shipping contaminated steroids in bulk across state lines. To hide the operation, Ronzio oversaw a nationwide scheme in which sales reps instructed customers to submit phony patient lists, appointment schedules, or rosters—paperwork later used to fabricate patient-specific prescriptions for FDA inspectors. In reality, NECC shipped vials without patient names, allowing clinics to use them on anyone—a flagrant violation of federal law.

The deception was calculated and systemic. Ronzio acknowledged that NECC owner and head pharmacist Barry J. Cadden created ratios dictating how many vials could be tied to a single patient to make the fraud appear plausible. Cadden told Ronzio: “The MAX total number of units (vials, syringes, etc.) per patient must make sense. I must be able to logically explain to a regulator why we processed x# of units per patient.” The goal: preserve NECC’s pharmacy license and evade the strict oversight applied to drug manufacturers.

The fraud directly enabled the 2012 fungal meningitis outbreak—the worst public health crisis ever linked to a pharmaceutical product. Contaminated vials of preservative-free methylprednisolone acetate (MPA) shipped from NECC infected 751 patients across 20 states. According to the Centers for Disease Control and Prevention, 64 of those patients died in nine states. The death toll, the CDC warns, continues to climb as long-term complications emerge.

Ronzio was one of 14 NECC owners, executives, and staff indicted in December 2014 following a two-year investigation. While not charged with direct involvement in manufacturing, Ronzio’s role in perpetuating the regulatory shell game was critical. He is now cooperating with federal prosecutors and is expected to testify against Cadden and supervisory pharmacist Glenn A. Chin, who face 25 racketeering acts of second-degree murder. Their trial is set for Jan. 5, 2017.

U.S. District Court Judge Richard G. Stearns scheduled Ronzio’s sentencing for Sept. 27, 2017. The case was brought by United States Attorney Carmen M. Ortiz, with investigations led by the FDA’s Office of Criminal Investigations, the FBI’s Boston Field Division, and the Department of Health and Human Services. The fallout from NECC’s greed and deception continues to reverberate through courtrooms and clinics nationwide.